Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

Leonard Joseph Appleman,Maneka Puligandla,Sumanta K. Pal,Wayne Harris,Neeraj Agarwal,Brian A. Costello,Christopher W. Ryan,Michael R. Pins,Jill M. Kolesar,Daniel A. Vaena,Rahul Atul Parikh,Mehmood Hashmi,Janice P. Dutcher,Robert S. DiPaola,Naomi B. Haas,Michael A. Carducci

Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

2019

Leonard Joseph Appleman
Maneka Puligandla
Sumanta K. Pal
Wayne Harris
Neeraj Agarwal
Brian A. Costello
Christopher W. Ryan
Michael R. Pins
Jill M. Kolesar
Daniel A. Vaena
Rahul Atul Parikh
Mehmood Hashmi
Janice P. Dutcher
Robert S. DiPaola
Naomi B. Haas
Michael A. Carducci

4502Background: Patients with no evidence of disease (NED) after metastasectomy for metastatic renal cell carcinoma (mRCC) are at high risk of recurrence, but no systemic therapy has been shown to ...

Keywords:

Metastasectomy
Renal cell carcinoma
Placebo
Pazopanib
Oncology
Disease
Pathology
Medicine
Internal medicine
in patient
Systemic therapy
double blind

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations